Whitehawk Therapeutics Q2 net loss narrows
Whitehawk Therapeutics Q2 net loss narrows
Overview
US oncology therapeutics firm's Q2 net loss narrowed
Q2 operating loss also narrowed
Lower R&D expenses drove improved results; prior year included $38 mln license fee
Result Drivers
LOWER R&D EXPENSES - Q2 research and development expenses fell due to absence of prior year's $38 mln license fee
Company press release: ID:nPn2WfTJya
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss | Beat | $16.64 mln | $22.29 mln (7 Analysts) |
Q2 Operating Income | Beat | -$18.11 mln | -$23.48 mln (6 Analysts) |
Q2 Pretax Loss | Beat | $16.64 mln | $22.88 mln (6 Analysts) |
Q2 Operating Expenses |
| $18.11 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $7.50, about 84.3% above its August 5 closing price of $4.07
Reuters Recommended Reads
Aug 6 - Cullinan Therapeutics Q2 net loss narrows
Aug 5 - Context Therapeutics Q2 net loss widens on higher R&D costs
Aug 6 - Iovance Q2 net loss narrows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)